Alar Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 0.8 million. Net income was TWD 1.73 million compared to net loss of TWD 12.06 million a year ago. Basic earnings per share from continuing operations was TWD 0.03 compared to basic loss per share from continuing operations of TWD 0.21 a year ago.
For the nine months, sales was TWD 0.8 million. Net loss was TWD 24.82 million compared to TWD 24.15 million a year ago. Basic loss per share from continuing operations was TWD 0.44 compared to TWD 0.42 a year ago.